Progyny, Inc. is A Promising Investment Despite Some Temporary Setbacks

Photo of author
Written By Nathan Goldstein

Progyny, Inc. is a promising investment consideration based on a positive long-term growth outlook. Despite a revenue miss in 1Q24, this is not seen as indicative of a structural impairment to growth.

Historical U.S. Assisted Reproductive Technology (ART) cycles suggest a solid long-term growth trend, with downturns typically followed by strong rebounds. Leading indicators suggest that utilization rates are already back on track.

Review of Latest Results

Credits: DepositPhotos

Progyny reported Q1 earnings in early May, with revenue growth of 7.6% to $278 million, missing the street expectation of $290 million. Fertility benefit services saw growth of 8.1% to $169.8 million, while pharmacy services grew by 6.9% to $108.3 million.

Gross margin declined by 18 basis points to 25.7%, while EBITDA margin expanded by 14 basis points to 18.1%, amounting to $50.3 million. Despite disappointing results, the revenue miss is viewed as a one-off issue rather than a structural problem, and the stock has dropped from approximately $32 to $26.

Understanding the Revenue Miss

The revenue miss was not due to structural issues. Utilization rates in January and February were in line with 2023, but saw a sharp decline in mid-March. This decline is attributed to patients adjusting expectations around access to maternal healthcare following the Alabama Supreme Court ruling, particularly in states with restrictive reproductive laws.

Utilization rates are believed to be delayed rather than permanently impaired. Recent legislative clarity is expected to improve the situation, and management has noted that utilization rates stabilized and improved in April.

Importantly, while utilization fell in states with restrictive laws, there was no decline in demand for PGNY’s fertility benefits among employers in those regions. This indicates that employees can continue to access affordable IVF, suggesting potential future demand and utilization.

Future Growth Expectations

Progyny is expected to see growth reaccelerate in the coming quarters, with several indicators suggesting solid demand. The year-to-date pipeline remains strong, with early commitments indicating increased adoption. The percentage of large employers offering IVF coverage has increased significantly, from 23% in 2019 to 45% in 2023. Engagement levels have also persisted above 2022 levels, indicating that the current increase in adoption and growth in the pipeline is not a one-off event.

IVF demand has historically been resilient, with ART cycles showing consistent growth over the past 20 years. During economic downturns such as the subprime crisis and COVID-19, ART cycle growth turned negative but rebounded strongly once the crises ended. This historical resilience supports the long-term growth outlook for Progyny.


Progyny is expected to accelerate growth back to over 30% once short-term issues are resolved and the economy recovers. Previously, growth was anticipated to reach over 30% in FY25, but this has been revised to FY26 due to current uncertainties.

Using revised FY24 revenue guidance of $1.25 billion, a linear expansion to 33% y/y growth rates is projected for FY26, leading to $1.66 billion in revenue. This is achievable given Progyny’s 38% growth last year.

The market is expected to react positively to growth acceleration, with PGNY trading up to at least 3x forward revenue, similar to its valuation in FY23 when growth was over 30%. Based on these assumptions, a target price of approximately $54 is set for FY25.

Risk Factors

Volatility in utilization rates may lead to conservative estimates from investors. Until Progyny shows improvement in utilization on a reported basis, the stock may remain rangebound. Additionally, if the economy continues to slow or enters a recession, Progyny will be directly impacted.

Strategic Positioning

Credits: DepositPhotos

Despite the revenue miss in 1Q24, Progyny remains an exciting investment. The long-term outlook for the business is positive, supported by historical trends showing resilient IVF demand and strong rebounds following economic downturns.

Leading indicators suggest that a rebound in utilization is already underway, reinforcing the growth prospects for Progyny.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.